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ABSTRACT 
 
Background: Chronic kidney disease and end stage kidney disease are becoming a huge health 
challenge. The optimal treatment is renal transplantation but due to low rates of 
transplantation most patients who are enrolled in the chronic renal replacement programme 
are on dialysis.  This study aimed at investigating demographic and social factors that are 
associated with the outcomes of peritoneal dialysis (PD). The study also investigates how co-
morbidity contributed to the outcomes of PD. 
 
Methods:  The study makes use of retrospective analysis of demographic data (age, marital 
status, residential area, race) and socioeconomic status, level of education, family support, 
poor access to health care system as well as co-morbidities and underlying cause of ESKD, 
obtained from 167 patients who were enrolled on continuous ambulatory peritoneal dialysis 
(CAPD) over the period of 2008 - 2012 at the Charlotte Maxeke Academic Johannesburg 
Hospital (CMJAH).  The data analysis for the present study was conducted using STATA version 
14.0. To describe the demographic characteristics of the patients, frequency tables were 
computed for all categorical variables. For continuous variables, the Shapiro Wilk test for 
normality was used to assess the distribution of the data to report the appropriate central 
tendency measure i.e. mean±SD or median (IQR). To assess the contribution of demographic 
factors to the overall outcome of CAPD, a Fisher’s exact test of comparison was used to assess 
the difference between the proportions for each demographic factor and CAPD outcome. The 
Fisher exact test was used because the proportions for each frequency table included a 
proportion below five (<5). To assess how the relationship of demographic and co-morbid 
disease affects the outcome of the treatment, a multivariate logistic regression model was fitted 
adjusting for co-morbid disease for each of the demographic factors. 
v 
 
 
 
Findings and interpretation:  Of 167 patients enrolled, the majority were black with low levels 
of education, living in townships and 56% were on subsisting on disability grants. PD failure 
occurred in 53.3% of patients over the study period and 46.7% were successful on PD. Of the 
variables tested, age was statistically significant  for CAPD outcomes [Fisher exact test (p= 
0.004)], indicating a significant difference in the proportion  of CAPD outcomes among 
different age categories). The univariate and multivariate logistic regression analysis did not 
show significant association with CAPD outcomes.   Adherence also significantly impacted on 
outcomes in both univariate and multivariate analyses, showing that non-compliant patients 
were less likely to have successful outcomes on PD. In addition, the Fisher exact test showed 
no significant difference in the distribution of CAPD outcome with marital status while the 
multivariate analysis showed that single patients were three times more likely to succeed with 
PD compared to married patients.   These could be due to chance, because of the small sample 
size, and require further investigation.  
    
Conclusions: Prospective studies are needed to fully understand the extent that demographic 
and socioeconomic factors impact on the outcomes of PD. This will assist in formulating 
comprehensive recommendations and ways to improve PD utilization and outcomes.   
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CHAPTER ONE 
1 Introduction 
 
Peritoneal dialysis (PD) is one of the treatment options offered for end stage kidney failure. 
There has been on-going research exploring the outcomes of PD and the factors that influence 
the outcomes of PD. This study focused on the demographic and social aspects and assessed 
if these had any contribution or association with the outcomes of PD in our setting. 
 
1.1 Background of Chronic Kidney Disease  
 
Chronic kidney disease (CKD) and end stage kidney disease (ESKD) are well recognised entities 
that are on the increase and becoming a health burden in developing countries (1). There are 
many causes of CKD, some of which are epidemic in certain countries. Although there has 
been much progress in renal replacement therapy (RRT), due to its expensive nature, most 
countries in the developing world do not offer the treatment(2). In South Africa, RRT is offered 
to a limited number of patients due to financial constraints. 
 
1.1.1 Definition and classification of chronic kidney disease 
 
Chronic kidney disease (CKD) involves a range of various pathophysiologic processes that 
result in progressive loss of kidney function and gradual decrease in glomeruli filtration rate 
(GFR) (3).The National Kidney Foundation (NKF) and Kidney Disease Outcomes Quality 
Initiative (KDOQI) classify the stages of CKD 
Table 1.1 according to the GFR (4). 
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Table 1.1  Stages of Chronic Kidney Disease 
GFR-Glomerular Filtration Rate, ESKD-End Stage Kidney Disease, TOD-Target Organ Damage 
(4). Krol G. Chronic Kidney disease staging and progression. American Society of Nephrology; 
2011; 6.0 :4-10 
 
KDOQI defines CKD as progressive irreversible kidney damage with GFR of less than 60ml/min 
per 1.73 for 3 months or more. End stage kidney failure corresponds to stage 5; at this point, 
the kidney is unable to excrete toxins, electrolytes and fluid.  Accumulation of the above 
products results in uraemic symptoms, which can lead to death if treatment in the form of 
dialysis or kidney transplantation is not initiated (4).  
 
 
Stage GFR in ml/min per 1.73m2 
0 >90 
1 
(p) 
Equal or more than 90, with TOD* or p if 
proteinuria 
2 
(p) 
60-89 age related decline in GFR with p if 
proteinuria 
3A   
                                                                                                          
3B 
(p)                                   
45-59 low risk of progression to kidney 
failure
30-44 
Additional suffix (p) means there is 
significant proteinuria 
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(p) 
15-29 high risk of progression to kidney 
failure 
Additional suffix (p) indicates that there is 
significant proteinuria 
5 
5D 
5T 
<15 
ESKD undergoing dialysis 
ESKD undergoing kidney transplant  
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1.1.2 Clinical Features of Chronic Kidney Disease  
 
The kidneys perform various vital roles; dysfunction affects multiple systems. Stages 1-3 are 
generally asymptomatic; as the disease progresses and GFR decreases, multiple toxins 
accumulate, resulting in uraemic symptoms that can manifest as encephalopathy, peripheral 
neuropathy, pericarditis and uraemic bleeding, among others. Altered salt and water handling 
results in fluid overload and electrolyte disturbance, which can present as cardiac arrhythmias 
which can be fatal. Haematological disorders and CKD metabolic bone disorder result from a 
reduction in hormones produced by the kidney (5). 
 
1.1.3   Causes of Chronic Kidney Disease 
 
Chronic kidney disease can result from multiple causes that can be congenital or acquired. 
The causes include hypertension, diabetic nephropathy, vascular disease, glomerular disease 
(which could be primary or secondary), cystic kidney disease, tubulo-interstitial disease, 
urinary tract obstruction or dysfunction, recurrent kidney stone disease and non-recovering 
acute kidney injury. There are multiple causes for each group (6).  
 
1.1.4 The Epidemic of Chronic Kidney Disease  
 
The increase in ESKD is becoming a huge public health burden due to the expensive and 
complex nature of the treatment. Therefore, more than half of the countries in Africa do not 
offer a public chronic dialysis programme (1). The optimal treatment of ESKD is kidney 
transplantation, but due to the low rates of transplantation, dialysis is the main means of 
intervention. The transplantation rate is 9.2 per million population (PMP) in South Africa 
annually and according to the South African Renal Registry in 2015, these were 13.4% of 
patients on RRT (7). This means that dialysis units are carrying a heavy patient load, with large 
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numbers awaiting transplantation (8). In addition, not all ESKD patients are eligible for 
transplantation, adding to the numbers on dialysis. 
 
1.1.5 Forms of Chronic Dialysis 
 
There are two forms of dialysis offered by the government of South Africa in the public sector. 
These are haemodialysis (HD) and CAPD. Worldwide HD is more prevalent than PD. South 
Africa has the largest number of patients on dialysis in Sub Saharan Africa, with 32% of dialysis 
patients on PD in South Africa (9). 
 
1.1.6 History of Peritoneal Dialysis 
 
The Greeks were the first to study the peritoneum while the Egyptians were the earliest 
anatomists to describe the extent of the peritoneal membrane, and named its surfaces and 
attachments. Christopher Warrick developed the initial concept of peritoneal dialysis from a 
novel treatment of ascites in the 1740s (10). Friedrich Daniel von Recklinghausen was the first 
to describe the gross and cellular anatomy of the peritoneal membrane in 1862, while Wegner 
discovered the basis for using the peritoneal membrane for fluid removal in 1877(10, 11). It 
was only years later in 1923 that George Ganter used peritoneal dialysis for the treatment of 
uraemia. It took several years for the discovery of a safe method of accessing the peritoneum 
through a catheter. Experiments were carried out with different materials, from metal to glass 
containers, polyethylene bags, to the Doolan catheter. It was in 1968 that Henry Tenckhoff 
finally patented a silicone catheter which is currently still in use. After overcoming the access 
problems, the challenges of peritonitis due to large numbers of connections and 
disconnections resulting from using glass containers containing PD solution had to be 
overcome. Disposable plastic bags were patented in 1978, and were subsequently followed 
by the double bag and Y system. This contributed  to the elimination of further connection 
issues, hence decreasing the risk of peritonitis (10, 11). 
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1.1.7 Regimen of Peritoneal Dialysis 
 
The two main regimens are the intermittent and continuous regimens. The intermittent 
regimen is mainly prescribed for patients with residual renal function and/ or high peritoneal 
transporter function status.   
The three schedules of intermittent regimens are:  
(i) intermittent peritoneal dialysis (IPD) which is a manual or automated form of PD 
where dwell time is 10 to 20 minutes and is mainly used for acute dialysis;  
(ii) nocturnal intermittent peritoneal dialysis (NIPD) which is performed by PD cycler 
at night, and   
(iii) tidal peritoneal dialysis (TPD) which has variable dwell times and incomplete 
drainage before the next dwell time.   
The continuous regimen, on the other hand, is made up of  
(i) continuous cycling peritoneal dialysis (CCPD) which uses an   automated machine 
to perform exchanges at night while the patient sleeps, with a long day day time 
dwell and  
(ii) continuous ambulatory peritoneal dialysis (CAPD),  where multiple manual 
exchanges performed during the day with an overnight dwell (12). 
 
The two main types of chronic PD are CAPD and APD. APD uses the automated cyclers which 
have built-in safety and warning devices, with some models able to adjust fluid volume. The 
dialysis is done at night for 8-10 hours, leaving the day time free (13).  In South Africa APD is 
mostly offered in the private sector.  
 
 
There are studies that showed that some patients were started on CAPD due to shortages of 
HD slots and long distances from the dialysis centres (14). In countries such as  Mexico, “PD 
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FIRST” is the initial mode of dialysis (15). Therefore, CAPD in some cases is offered as the first 
modality of RRT. 
 
1.2 Studies Assessing Outcomes of CAPD 
 
Most studies assessed the outcomes in terms of looking at patient survival and technique 
survival. An example is the study in Korea which assessed the long term outcomes of PD over 
a 25 year period where technique survival at 5 and 10 years was 71.9% and 48.1% respectively 
while patient survival was 69.8% and 51.8% respectively (16). These included infectious or 
non-infectious complications which lead to hospitalisation, morbidity and mortality as well as 
failure of PD, resulting in transfer to HD (16). It also includes patients who had a kidney 
transplant while on peritoneal dialysis, as well as those who are currently on PD. A large 
incident cohort study by Pajek et al showed an outcome probability of 0.69-0.53 at 3 and 5 
years for patient survival (including those transplanted from PD) and 0.33-0.43 for technique 
failure respectively, with majority of technique failure caused by peritonitis and only 6.3% 
caused by poor ultrafiltration (17). It also reported on the patients who were lost to follow up 
or those whose dialysis was terminated because of non- compliance or other reasons. The 
study in China is another example where 1321 patients were followed up  for median of 34 
months ((IQR 21-48 months) and had the following clinical outcomes:  19.8% deaths, 8.4% 
transfer to HD, 16.5% transplanted, 3.2% lost to follow up and 1.4% were still on PD treatment 
(18). 
 
 Jain A et al showed that the crude total number of patient receiving PD has increased over 
time in both developed and developing countries (19). With the increased use of CAPD, there 
have been studies assessing the impact of dialysis adequacy on outcomes of PD, as well as 
new developments through the years to improve the outcomes of PD. CAPD has  been  proven 
to have good outcomes and has several advantages, especially in the first two years of dialysis 
(20), Heaf  et al showed PD mortality relative to HD after correcting for comorbidity and 
transplant candidacy to be 0.65 (CI 0.59-0.72, P <0.001)  and the difference was confined to 
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the first two years of dialysis (20). It seems that it may be advantageous for CAPD to be the 
initial modality of dialysis, though there is still some debate about this (21), due to conflicting 
results.  Bloembergen et al showed that CAPD/CCPD had 19% higher mortality than HD (22) 
while Fenton et al  showed a 27% lower mortality risk with PD compared with HD (23).  Collins 
et al showed that CAPD/CCPD had outcomes comparable with / significantly better than HD, 
which varied over time, and reached a conclusion that CAPD/CAPD was associated with 
superior outcomes in the first two years of dialysis (21).   
 
There has been growing interest in the factors that can influence the outcomes of PD so as to 
improve the overall outcomes, especially in developing countries. There have been conflicting 
outcomes of different studies, regarding which factors are associated with adverse outcomes 
of CAPD. An example of these studies is the retrospective study over 5 years in Saudi Arabia 
where the peritonitis rate was 0.4 episodes per year, with a 30% exit site infection rate; 12.5% 
had catheter-related complications and 11% developed hernia. At the end of the study, 41% 
were still on PD; 30% received kidney transplants; 13% suffered technique failure and were 
transferred to HD, while 9% died. They concluded that the PD related complication rate was 
low in their programme with low morbidity and mortality.The authors concluded that PD is a 
safe and effective treatment modality in the integrated care of patients with ESKD (24).    
 
A prospective study of PD was undertaken at Chris Hani Baragwanath Hospital using the Bara 
adapted adequacy compliance scoring system (BAD-C score). BAD-C score  was an assessment 
of  adequacy of compliance which was scored as excellent, good, fair and poor, where 
excellent was awarded to the patients who attended more than 90%  of the monthly clinic 
visit and poor if  they attended less than 50% of clinic, while clinical status was  evaluated by 
experienced health workers when the patients presented with peritonitits by comparing hand 
hygiene, bag connection and disconnection to the previously taught method and scoring 
them. Clinical outcomes were assessed as achieving dry weight, creatinine less than 1200, 
haemoglobin level 8-10g/dl calcium and phosphate level less than 5. They were scored as 
excellent, good, fair or poor.  Patients who met all acceptable parameter were scored 
excellent  and scored poor if they did not meet any. The low BAD-C score was a significant 
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indicator of CAPD failure (p= 0.001). The study  showed that ‘the peritonitis rate and causes 
are similar to the developed world; socioeconomic factors did not appear to influence 
peritonitis rates or CAPD failure’ (25). The study enrolled eighty four patients and peritonitis 
rate was one episode every 27.9 patient months, attrition to HD was 16.6% (n= 14) of patients, 
loss to follow up was 28.8 %; 14 patients regained renal function  or were transplanted. A low 
BAD-C score was associated with a higher rate of peritonitis, with higher rates of CAPD failure 
(P= 0.0001) (25). 
 
A study from Cape Town showed that the rate of peritonitis was significantly associated with 
overcrowding, lack of electricity, living in informal settlements, level of education and black 
race (1). Another study from Cape Town also showed that higher rates of peritonitis were 
associated with high occupancy and bedroom ratio, absence of electricity, informal housing, 
number of years of education and black race. Further multivariate analysis demonstrated that 
poor social circumstances (P=0.005), and not race, were the determining factors for 
peritonitis and PD failure (26).  
 
A study done in Natal showed that poor socioeconomic status, inadequate sanitary 
conditions, lack of motivation and acceptance of chronic disease together with tribal customs 
and belief in traditional healers hampered acceptance of CAPD (27). Another study from the 
same centre showed that black patients had a 6-fold higher risk of developing peritonitis than 
other ethnic groups. This was attributed to factors such as living in less  developed 
environments, lower levels of education, poor housing and lack of electricity and water (28). 
Other studies have identified demographic factors like black race, younger age, gender, single 
status, low socioeconomic status, low educational level, rural setting, difficult transportation, 
lack of electricity, limited access to good sanitation, poor water resources, unstable living 
conditions and limited numbers of nephrologists as major obstacles for successful PD 
encountered in developing countries (1, 29) 
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A study in Limpopo province showed that low income did not predict outcomes of  PD. In this 
study, 71% of the patients were unemployed with more than 50% of the patient’s having a 
total anual income of less than 180 US dollars, only 41% had tap water at home and having to 
travel an average distance  of 122.9 ± 78.2 km to the dialysis unit. The study  demonstrated 
that despite predictors of outcome like remoteness of the dialysis unit, unavailability of tap 
water or electricity at home or poverty due to unemployment and insufficient income were 
not predictive factors. The overall peritonitis rate was 0.82/year and 1 year, 2 year and 5 year  
patient survival was 86.7%, 78.7%, 65.3% with 83.3%, 71.1%, 62.1% technique survival 
respectively. Instead, serum albumin (p=0.030), haemoglobin (0.002), body mass index 
(p=0.011), and recurrent peritonitis (0.038) were the factors that predicted the overall 
outcome of peritoneal dialysis (30). It is however difficult to properly evaluate the impact of 
low socioeconomic factors on CAPD outcome in these studies because 75% patients of the 
patients were from a low socioeconomic background.  
 
A  study from Hong Kong reported a higher risk of peritonitis with younger age, illiteracy and 
poor income on a disability grant (31). In another study, low income and educational levels  
were associated with all cause of mortality, while in the multivariate cox regression analysis 
age, BMI, diabetes mellitus, cardiovascular disease,  haemoglobin and albumin,  centre size 
were associated with all cause mortality. Poorer/ low income patients (p= 0.001), gender (p= 
0.001), less educated patients with no diploma (p=0.02), who live in underdeveloped areas 
were at a higher risk of mortality and morbidity associated with PD (32).  However, it has been 
shown that only impoverishment, the need for assistance to perform dialysis and allocation 
to PD therapy by the physician (instead of PD being the patient’s choice) were associated with 
poorer technique success (33). In this study, factors like age, education, marital status, 
gender, rural home and diabetes mellitus were not the major risk factors (33).  
 
The literature has identified patients with the following problems: metabolic syndrome, 
elderly diabetic females, poor residual renal function, low serum albumin and low 
haemoglobin and previous history of cardiovascular disease as predictors of poorer outcomes 
on CAPD. Serum albumin was found to the best predictor of the outcome of PD (34). 
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Family support is associated with successful adaptation and compliance with dietary 
requirements. It is said that the main factor for patients discontinuing dialysis is as a result of 
their perception that they are a burden to their immediate family (35). Therefore, knowledge 
of the way that patients experience their disease and its treatment is important (36), and 
family involvement and support plays a major role in the outcome of PD. 
 
1.3 Demographic and Social Factors in South Africa 
 
Chronic kidney disease and ESKD affects mostly young adults, age 20 to 50 years, in Sub 
Saharan Africa (37). Chronic glomerulonephritis, hypertension, HIV associated nephropathy 
and diabetes mellitus form the bulk of the aetiology of ESKD (35,7). Worldwide, black adults 
have a higher incidence of hypertension, which also tends to be more severe; these patients 
tend to have a higher risk of ESKD and develop CKD at an earlier age (37). Hypertensive 
nephropathy was present  in 34.6% of black patients, 20.9% of the mixed race group, 13.9 % 
Indians and 4.3 % whites on RRT(2). Diabetic nephropathy affects 14.4 % of ESKD patients on 
RRT and 9.4% of ESKD patients on RRT had HIV associated nephropathy, with the majority of 
the patients being black (7). 
 
1.4 Social Factors in South Africa 
 
Historically, most patients in South Africa who are treated at government hospitals are less 
privileged, with lower levels of education and low or no income requiring disability grants. 
Patients living in rural areas have limited access to medical care, and often present late with 
ESKD. For such patients, transport to a dialysis centre can be challenging. In addition, due to 
rapid urbanization, patients accessing state sector facilities often reside in overpopulated 
areas or informal housing with no electricity and poor sanitation, which increases the risk of 
adverse outcomes (14).  There has been evidence in the literature that showed that 
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educational levels, geographic factors, centre size and race are associated with a higher risk 
for peritonitis in Brazil, independent of socioeconomic status and peritoneal dialysis modality 
(38). 
 
1.5 Continuous Ambulatory Peritoneal Dialysis 
 
CAPD was first introduced in South Africa in 1978, and has since gained momentum due to its 
clinical advantages (Table 1.2) and significant reduction in its complications (peritonitis), with 
the introduction of the following techniques: twin bag and Y systems (Figure 1.1; Table 1.2),  
flush before fill technique as well as the use of bactroban and gentamycin ointments for exit 
site care.  There has been increase of PD to 24.9 patients per million population in the 
developing countries and 21.8 per million populations in developed countries. In South Africa 
13.9 % of patients on RRT  are on PD, which is more than previous years (7). There is  a decline 
in the use of  PD in the developed countries while there is no significant decline noted in 
developing countries (19). The decline could be possible due to the disadvantages of PD 
(Table 1.3), amongst other challenging reasons (39). 
 
Figure 1.1 CAPD Procedure 
(Source: National Institute of Diabetes and Digestive and Kidney Disease, National Institutes 
of Health) (40). Reproduced with permission from NIDDK. 
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1.5.1 Advantages of CAPD over HD  
 
Table 1.2 lists the advantages of CAPD and table 1.4 its disadvantages, in comparison with HD. 
 
Table 1.2   Comparison of the advantages of CAPD and HD  
Advantages CAPD HD 
Preserve residual renal function YES NO 
Preserve vascular site YES NO 
Convenience of home therapy  YES NO 
Flexible hours therefore more freedom YES NO 
Patient more in charge of their lives YES NO 
Psychological advantage (less depressed) YES NO 
Safer in patient with cardiac instability and insulin 
dependent diabetes mellitus 
YES NO 
Less delayed graft function post  kidney transplant  YES NO 
Sinnakiroucheman R, Holley JK. PD versus HD: Risk benefits and access issue. Advance  in 
Chronic Kidney Disease 2011: 18 (6): 428-432 (41) 
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Table 1.3 Comparison of the disadvantages of CAPD and HD  
Disadvantage CAPD HD 
Continous therapy: No day off, leading to patients and family 
burnout 
 YES  NO 
Body image concerns due to presence of catheter and fluid in 
the abdomen 
YES NO 
High technique failure rate YES NO 
Space needed for monthly supplies of dialysis equipment/ 
Solutions 
YES NO 
Inability to lift more than 25Ibs YES NO 
Non-compliance can lead to complications YES YES 
Risk of malnutrition due to glucose contained in dialysis 
solution 
YES NO 
Peritoneal membrane failure YES NO 
Ellam T, Wilkie M. Peritoneal dialysis. Medicine. 2015; 43 (8): 484-488  (42) 
 
1.5.2 Requirements for CAPD 
   
In order to carry out CAPD independently, patients must at least meet the following criteria 
(43):  
• physical capability (visual acuity and limb dexterity) 
• psychological capability to undertake repetitive bag changes as per protocol 
• access  to clean water 
• abdomen with no previous surgery or at most a mini-lapataromy  
Patients should agree to the therapy and should be educated about other options and 
limitation of resources. Additional requirements for PD are storage space for dialysis fluids 
and adequate hand washing facilities; hence home visits are recommended prior to starting 
PD. Ideally the patient should not have had any abdominal surgery and abdominal muscles 
should be reasonably strong. (43)  
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1.5.3 Initiating CAPD  
 
Peritoneal dialysis is started in eligible patients with ESKD. However, it may be delayed for a 
short period if the patient is asymptomatic (not uraemic, fluid overloaded and the serum 
albumin is stable), while the patient is being educated about PD, and prepared for life 
adjustment by involving a social worker, psychologist and family member to assist, where 
needed, so that the patient is psychologically and emotionally equipped with coping skills to 
increase the compliance and success rate of PD.  The IDEAL study showed no difference in 
mortality between the early start (GFR of 10-14 ml/min) and late start group (GFR of 5-7 
ml/min); 70% of the late start group started at GFR of 7ml/mim/1.72m2 due to uraemic 
symptoms, and 60% of the patients were started on PD; the participants were considered to 
be well prepared and well nourished. (44).  
 
However, the above scenario is mostly in an ideal situation, as most of the patients present 
late and are symptomatic, with little time to adjust to ESKD and its treatment.  In most cases, 
patients present needing emergency dialysis and are started acutely on HD, while they are 
being assessed. They are then educated about PD and, subsequently converted to PD. They 
therefore have little time to accept and adapt to the diagnosis and the treatment (45). 
 
Ideally once PD has been initiated, the Peritoneal Equilibrium Test (PET) is done in two weeks 
to determine the individual's peritoneal membrane characteristics and to determine the 
appropriate prescription for PD. This should be done every six months to twelve months, 
unless the prescription changes or peritonitis has occurred (46).  However PET is not routinely 
done in CMJAH. 
 
 
 
15 
 
 
1.5.4 How Peritoneal Dialysis Works  
 
 PD is the process whereby fluid and solutes (albumin, glucose, urea and other small 
molecules) diffuse across the peritoneal membrane from the blood to the peritoneal cavity 
across a concentration gradient. Fluid is introduced into the abdominal cavity via a catheter 
and cycled either at night when the patient sleeps (automated PD), or exchanges are carried 
out about 4 times a day over the twenty four hours period (CAPD). The fluid (which is known 
as dialysate) is infused and remains in the abdomen for 4-6 hours, during which solutes move 
from high concentration in the blood into the dialysate in the peritoneal cavity; fluid is then 
allowed to drain out by gravity until the next cycle, (see Figure 1.2)  
 
              A                               B                               C                       D                          E 
Figure 1.2 Demonstration of how PD works 
(Source: Reprodueced with permission from the National Institute of Diabetes and Digestive 
and Kidney Disease, National Institutes of Health)  (40) 
 
Picture A shows how the patient is hooked-up, followed by infusion of dialysis fluid into 
peritoneal cavity Picture B known as fill phase. Picture C and D  are called  dwell time where 
diffusion takes place. Picture E shows drainage phase 
 
There is a concentration gradient between the blood and dialysate which enables small 
molecular weight substance to diffuse across the concentration gradient.  The dialysate is 
allowed to dwell in the peritoneum for a certain period until the concentration gradient 
equilibrates and there is no further difussion of molecules down the concentration gradient 
(47). Ultrafiltration, which is the net movement of  water, depends on  the osmotic  gradient 
created by the glucose in the dialysate and the patient’s blood glucose as well  as the rate of 
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absorption of glucose itself from the PD fluid; in addition, aquaporin 1 are  utltra small pores  
which are responsible  for  transcellular water permeability resulting in ultrafiltration (48).  
 
1.5.5 Adequacy of Peritoneal Dialysis 
 
There are controversies with regards to the optimum method to assess PD adequacy. There 
are several methods to assess PD adequacy using liberal clinical criteria including (49):  
• feeling of wellness 
• absence of uraemic symptoms 
• reasonable control of clinical parameters (acid base, blood pressure control, fluid 
status, cardiovascular risk factors, diet and nutrition, mineral and bone disorder).   
Solute clearance can also be calculated using urea and creatinine clearance with a minimum 
acceptable target for Kt/V for urea of 1.7. Kt/V also has its limitations; it only measures 
changes in urea, it does not measure middle molecules, excludes the role of ultrafiltration 
and does not take into account the mass exchange between body compartments and across 
the plasma membrane.   
 
1.5.6 Outcomes of Peritoneal Dialysis 
 
Outcomes  of   PD  may be  influenced by complications  which  can be divided   into  infectious 
and non infectious complications. These  complications   can lead to hospitalisation,  failure 
of PD resulting  in transfer to HD, and other  morbidity and mortality. Some patients may 
remain on PD for a very long time or until they receive a kidney transplant.   
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1.5.7  Infectious Complications of PD 
 
Peritonitis is the leading complication of PD. It accounts for about 18% of infectious episodes 
leading to PD mortality. Death directly attributed to peritonitis occurs in 4% of patients and 
peritonitis is a contributing factor in 16% of mortalities. It is the leading cause of technical 
failure and a major reason for conversion from PD to HD (50). 
 
TB peritonitis is more common in CKD, due to decreased cellular immunity. It usually occurs 
within 12 months after initiation of PD (50). 
 
Catheter sepsis: accounts for about 39% of the catheters removed. There are two forms:          
(i) exit site infection which is diagnosed by inflammation and a purulent discharge around the 
exit of the catheter and (ii) tunnel infection which is inflammation around the subcutaneous 
tract which may be clinically occult (50).  Association of peritoneal catheter exit-site infections 
and peritonitis has been recognised since the 1980s. Patients with a  history of exit site sepsis 
and tunnel infection were found to be at higher risk of developing peritonitis especially if 
there was a history of recurrent purulent exit wound infection (50). In most cases, exit wound 
and /or tunnel infection is found in patient with peritonitis (50). 
 
1.5.8  Non -infectious complications of PD 
 
 Non infectious complications can be subdivided into catheter related complications which 
are catheter malposition, kinking or blockage of the catheter, migration and entrapment of 
the catheter as well as catheter cuff extrusion. The non-catheter related complications are 
intra-abdominal pressure-related complications (hernia, abdominal leak, hydrothorax, genital 
prolapse and incontinence, constipation, deep vein thrombosis which increases the risk of 
pulmonary embolism), glucose induced metabolic complication (poor glycaemic control in 
diabetic patients, obesity, hypertriglycaemia, hepatic subcapsular steatosis) and other 
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complications like haemoperitoneum, intestinal perforation, peritoneal membrane fibrosis 
and loss of residual renal function (51). 
 
1.6 Problem Statement and Justification 
 
There is a world - wide increase in ESKD and South Africa is no exception. CAPD is gaining 
momentum in South Africa due to lack of HD slots. CAPD has been shown to have several 
advantages over HD in the first few years of starting dialysis (20). There is evidence indicating 
that patients' characteristics influence the outcome of CAPD (36) even though there is no 
consensus in the literature.  This study therefore further explores the impact of patients’ 
demographic and socioeconomic status on the outcome of CAPD at Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH).  
 
1.7 Research Hypothesis 
 
According to statistics of the South African Renal Registry in 2015, there were 13.9 % of 
dialysis patients on PD, of these paients  29% were in public sector and 7% in private  facilities 
(7).  A significant percentage of PD patients reside in South Africa (13). The study hypothesis 
is that the following variables are contributors to outcomes of CAPD in this setting: 
1. Demographic ( age, marital status, residential area, race) 
2. Socioeconomic status, level of education, family support, poor access to the health 
care system 
3. Co-morbidity and underlying cause  of ESKD 
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1.8 Study Objectives 
 
1.8.1 Primary Objective 
 
To assess the factors that contributed to the overall outcomes of CAPD at CMJAH (2008-2012). 
 
1.8.2  Secondary Objective 
 
Secondary objectives of the study are: 
1. To assess the contribution of demographic factors (age, race, socioeconomic status, 
marital status, geographical location, level of education) to the overall outcome of 
CAPD. 
2. To assess the relationship of demographic and co-morbid disease with the outcome 
of the treatment. 
3. To assess if the above mentioned factors have any predictive value on the outcome of 
CAPD. If it is feasible to predict the likely CAPD outcomes based on these factors, to 
be able to identify those patients that are more likely to be complication -free.  
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CHAPTER TWO 
2 Materials and Methods 
 
2.1 Study Setting 
 
The study was conducted at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in 
the PD unit, which offers both inpatient and outpatient management of CAPD patients. 
Patients are seen by doctors at least once a month. However, the unit is open from Monday 
to Friday, where patients can arrive anytime between 08:00-16:00 if they have problems and 
relevant management is offered. An after-hours on-call service is offered for emergencies. It 
is also available for patients who are hospitalised, or who are being initiated on CAPD. Patients 
initiated on CAPD are hospitalised for about a week or more to be educated and trained on 
CAPD and to ensure that CAPD is working effectively. Assessments are made to ensure that 
patients’ training is adequate. 
 
2.2 Study Sample     
 
The study population included all patients who attended the CAPD clinic at CMJAH from 2008 
to 2012. There are 80 slots allocated for PD by the CMJAH  administration. Every year about 
20 new patients are enrolled, depending on the number of PD slots available. A list of eligible 
patients awaiting a PD slot is maintained.  
 
2.3 Sample Size 
 
The sample included all patients who were enrolled on CAPD from 2008-2012. A total of 167 
patients were included in the study. 
21 
 
 
2.4 Ethical Approval 
 
Approval for the study was granted by Human Research Ethics Committee (HREC) (medical); 
clearance certificate No. M131029.     
 
2.5 Inclusion Criteria 
 
All ESKD patients who had been initiated on CAPD between 2008-2012 were included in this 
study. 
2.6 Exclusion Criteria 
 
Patients on CAPD whose records could not be retrieved; records were available for all  
patients in this study. 
 
2.7 Study Design 
 
The study design encompassed a retrospective review and analysis of the patients’ records, 
including blood results. Unfortunately, dietician/social worker/ psychology reports were 
unavailable for analysis for the majority of the patients.   
 
2.8 Definitions  
 
Township Location:  the underdeveloped urban areas or informal settlements occupied 
mostly by the non- white population of South Africa.  
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Suburb:  areas which are fairly developed and demarcated, usually with good levels of 
sanitation, electricity and water supply. These areas were historically occupied by white 
people.  
 
Blood pressure:  all the patients who had been diagnosed with hypertension by their 
attending physicians, and who were on treatment for high blood pressure. 
 
Cardiovascular diseases: were defined by the presence of left ventricular hypertrophy on 
echocardiogram or hypokinetic wall motion on echocardiogram or reduced ejection fraction 
on echocardiogram; or heart failure clinically; or history or ECG evidence of myocardial 
infarction or ischaemic heart disease. 
  
Fluid overload: was mainly determined from the clinical notes, where the patients were 
documented to be fluid overloaded during one of their visits. 
 
Peritonitis: was defined by the treating physicians by the clinical features  in keeping with 
peritonitis (like abdominal pain or cloudy peritoneal fluid), as well as  dialysate (after dwell 
time of at least 2 hours) showing an elevated white cell count of more than 100 cells/ml  with 
more 50% polymorphonuclear cells and positive culture of dialysis fluid. 
 
Non-adherence: was defined by patients documented to be non compliant in their files or 
who had signed warning letters after being assessed as being non compliant. Patients were 
said to be non compliant when they  defaulted monthly follow up or were admitted frequently 
with fluid overload after excluding tenkoff related problems  or  membrane failure and 
responded well to the same prescription when dialysed as an inpatient  under supervision of 
the nursing staff. 
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Outcomes: was defined as technique survival as well as patient survival (patients still on PD) 
as well as patients who were transplanted while on PD, patients transferred to another 
centre. PD failure was the patients who demised while on PD, and those who were converted 
to haemodialysis. 
 
2.9 Statistical analysis   
 
2.9.1 Data preparation 
 
The data for the study was collected manually from patient files and entered into an Excel 
spreadsheet. The data preparation procedure entailed a process of cleaning the data through 
checking for errors in recording, duplicates within the data and missing values. To verify 
accuracy, the patient files were used to verify that the data was recorded correctly. In 
preparation for data analysis, the study variables were coded and grouped to meet the study 
objectives. 
 
A CAPD outcome which was recorded as a binary variable was generated by recording all 
patients who were still on peritoneal dialysis (PD) or who were transplanted while on PD as 
PD success, while patients who were transferred to haemodialysis, lost to follow up, had 
complications leading to failure of PD or died were recorded as PD failure. Hence the outcome 
variable was coded as a binary variable (1=PD success, 2=PD failure). There were six 
demographic factors considered as independent variables for the study, namely: age, gender, 
marital status, employment, race and place of residence. The age of the patients was 
recorded as a continuous variable and was then recoded as a categorical variable (1 = 15-20 
years, 2= 21-30 years, 3=31-40 years, 4=51-60 years). The gender of the patients was coded 
as a binary variable (1=male, 2=female). The marital status of the patents was also coded as 
a binary variable (1=married, 2=single). The education level of the patients was coded as an 
ordinal categorical variable (1= no matric, 2=matric and above,3=unknown). The employment 
status the patients was coded as a nominal categorical variable (1=employed  
2=unemployed). The race of the patients was also coded as a nominal categorical variable 
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(1=black, 2=indian, 3=white). Lastly, the place of residence of the patients was coded as a 
binary variable (1=township location, 2=suburb). Patients were also categorized based on the 
presence or absence of the following co-morbidities: hypertension, diabetes mellitus, HIV and 
cardiovascular disease.  
 
2.9.2 Data Analysis 
 
The data analysis for the present study was conducted using STATA version 14.0. To describe 
the demographic characteristics of the patients, frequency tables were computed for all 
categorical variables. For continuous variables, the Shapiro Wilk test for normality was used 
to assess the distribution of the data to report the appropriate central tendency measure i.e. 
mean±SD or median (IQR). To assess the contribution of demographic factors to the overall 
outcome of CAPD, a Fisher’s Exact test of comparison was used to assess the difference 
between the proportions for each demographic factor and CAPD outcome. The Fishers Exact 
test was used because the proportions for each frequency table included a proportion below 
five (<5). To assess how the relationship of demographic and co-morbid disease affects the 
outcome of the treatment, a multivariate logistic regression model was fitted, adjusting for 
comorbid disease for each of the demographic factors. The logistic regression was used 
because the outcome variable, CAPD is a binary variable. 
Note: Fischer’s Exact is a test of comparison of proportions and logistic regression is a test of 
association. 
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CHAPTER THREE 
3 Results 
 
 Table 3.1 defines the demographic characteristics of the study population. The majority 
(59.2%) of the patients were young (40 years of age or younger); 56.9% were male; 86.8% 
were black; 61.7% had completed high school or tertiary education; 60.5% were unemployed; 
and 69.5% lived in townships/locations. 
 
Table 3.1 Demographic characteristics of the study patients  
Characteristic  
Total patients 167 
Frequency  
 
%  
 
Age group  
15-20 years  7 4.19 
21-30 years 27 16.67 
31-40 years                                64 38.32 
41-50 years  43 25.75 
51-60 years  25 14.97 
>60 years  1 0.60 
Gender  
Female  72 43.11 
Male  95 56.89 
Marital status  
Married  78 46.71 
Single  88 52.69 
Unknown 1 0.60 
Education  
No matric  13 7.78 
Matric and above 103 61.68 
Unknown 51 30.54 
Employment 
Employed  66 39.52 
Unemployed  101 60.48 
Race  
Black  145 86.83 
Indian  6 3.59 
White  16 9.58 
Place of residence   
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Township/ Location  114 68.26 
Suburb  51 30.54 
Unknown  2 1.20 
      
 Mean  SD  
Age  38.72 10.68 
 Median  IQR  
Weight  54 30-74 
 
 Comorbid conditions present in the study population are depicted in Table 3.2; 91% of the 
patients had hypertension; approximately 12% had diabetes mellitus; 20.4% were HIV 
positive and 18.6% had concomitant cardiovascular disease.  
Figure 3.1 shows the distribution of patients on CAPD patient receiving disability grants 
according to age  
 
Figure 3.1 Patients Disability Grants within Age Groups, with 56 %  of patients receiving 
disability grants 
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Table 3.2 Distribution of patients by comorbid disease 
Comorbid disease  Frequency  %  
Hypertension    
Absent  15 8.98 
Present  152 91.02 
Diabetes    
Absent  142 85.03 
Present  20 11.98 
Unknown  5 2.99 
HIV    
Negative  131 78.44 
Positive  34 20.36 
Unknown 2 1.20 
Cardiovascular disease    
Absent  131 78.44 
Present  30 17.96 
Unkown  6 3.59 
 
 
Figure 3.2 Distribution of the study outcome (CAPD) 
 
Out of the 167 patients, 78 patients (46.70%) were determined as PD success and 89 patients 
(53.29%) as PD failure over a period of 5 years (Figure 3.2). 
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Figure 3.3 Distribution of CAPD outcome by Age Group (Fisher exact test p-value =0.044).This 
figure shows that there is statistical significance between the distribution of CAPD outcome 
with age 
 
 
 
Figure 3.4 Distribution of CAPD outcome by Gender (Fisher exact test p-value =0.211). This 
figure shows that there is no statistical significance with distribution of CAPD outcome by 
gender. 
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Figure 3.5  Distribution of CAPD outcome by Marital Status (Fisher exact test p-value =0.103). 
This figure shows that there is no statistical significance with the distribution of CAPD 
outcomes by Marital Status 
 
Figure 3.6  Distribution of CAPD outcome by education level (Fisher exact test p-value =0.507) 
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Figure 3.7  Distribution of CAPD outcome by employment status (Chi-2 p-value =0.956). This 
figure shows that there is no statistical significance of distribution of CAPD outcome by 
employment 
 
 
Figure 3.8 Distribution of CAPD outcome by race (Fisher  exact test p-value =0.340) 
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Figure 3.9 Distribution of CAPD outcome by place of residence (Chi-2 p-value =0.365). This 
figure shows that distribution of CAPD outcomes by the place of residence 
 
Table 3.3 Distribution of CAPD outcome by comorbid disease  
 PD failure  PD success  p-value* 
Diabetes    
negative  70 (83.33) 75 (90.36) 
0.431 positive  12 (14.29) 8 (9.64) 
Hypertension    
negative  9 (10.71) 6 (7.23) 
0.227 positive  75 (89.29) 77 (92.77) 
HIV     
negative  67 (79.96) 64 (77.11) 
0.340 positive  15 (17.86) 19 (22.89) 
Cardiovascular 
disease     
negative  64 (82.05) 67 (80.72) 
0.829 positive  14 (17.95) 16 (79.28) 
 Distribution  of CAPD  outcome by cormorbid disease (The Fisher exact test showed no significance)  
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Figure 3.10 Distribution of the study outcome by adherence status (Chi-2 p-value =0.017) 
 
Table 3.4 Univariate logistic regression to determine the association between Demographic/ 
Clinical factors and the CAPD outcomes 
Characteristic 
 
Odds 
Ratio 
 
95 % Confidence 
interval 
p-value 
  
Age 1.00 0.97-1.03 0.990 
Gender (base=female)   
Male  0.65 0.35-1.21 0.172 
Marital status (base=married)   
Single 1.66 .0.90-3.01 0.107 
Education level (base =unknown)   
No Matric 0.46 0.13-1.69 0.244 
Matric and  above 0.94 0.48-1.85 0.866 
Employment (base=unemployed)   
Employed 1.01 0.55-1.90 0.956 
Race (base=black    
    Indian  0.52 0.09-2.93 0.469 
    White 0.47 0.145-1.46 0.186 
Place of residence (base=location)   
suburb  0.75 0.38-1.47 0.404 
Hypertension (base = no)    
Yes 1.35 0.46-4.00 0.586 
Diabetes (base =no)    
  Yes 0.7 0.28-1.85 0.489 
PD Failure; 
Compliant; 51
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Non-compliant; 
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Lost; 1
PD Success; 
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HIV (base =negative)    
  Positive  1.33 0.62-2.84 0.458 
Cardiovascular disease (base=no)   
Yes 1.50 0.67-3.33 0.320 
Infectious complication (base=no)   
Yes 0.77 0.41-1.45 0.428 
non infectious complication (base=no)   
Yes 0.93 0.47-1.80 0.827 
adherence (base=no)    
non compliance 0.81 -1.408-1.44 0.018 
 
Univariate logistic regression was carried out to determine the association between 
demographic/ clinical factors and successful CAPD outcome (Table 3.4). Univariate logistic 
regression showed that patients who were non-adherent were less likely to be a PD success, 
in comparison to patients who were adherent with CAPD (OR=0.81; 95% CI=-1.408-1.44; 
p=0.018). 
 
Table 3.5 Multivariate logistic regression to determine the association between demographic 
factors adjusted for co-morbid conditions and the CAPD outcome  
Characteristic 
 
Odds 
Ratio 
 
95 % Confidence 
interval 
p-value 
  
Age 1.01 0.96-1.05 0.552 
Gender (base=female)   
Male  0.71 0.35-1.46 0.351 
Marital status (base=married)   
Single 3.02 1.17-7.75 0.021 
Education level (base =unknown)   
No Matric 0.34 0.79-1.46 0.146 
Matric and  above 0.97 0.39-2.50 0.951 
Employment (base=unemployed)   
Employed 1.06 0.45-2.50 0.951 
Race (base=black    
    Indian  0.489 0.06-3.89 0.496 
    White 0.663 0.14-2.98 0.951 
Place of residence (base=location)   
suburb  0.99 0.37-2.64 0.990 
Hypertension (base = no)    
Yes 0.85 0.20-3.84 0.825 
Diabetes (base =no)    
    Yes 0.60 0.18-2.01 0.409 
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HIV (base =negative)    
    Positive  1.23 0.52-2.87 0.639 
Cardiovascular disease (base=no)   
Yes 2.76 0.95-7.97 0.325 
Complication infectious (base=no)   
Yes 1.16 0.47-2.86 0.751 
Complication Noninfectious (base=no)                   
Yes 1.11 0.39-3.11 0.845 
Adherence (base=no)    
non adherence 0.336 0.153-0.738 0.007 
 
Multivariate logistic regression was carried out to determine the association between  
demographic factors adjusted for co-morbid conditions and the CAPD outcome  (table 3.5). 
The multivariate analysis assesses the collective effect of the demographic and comorbid 
factors on the CAPD outcome, and showed that, when adjusting for all demographic and 
clinical factors, marital status and adherence were significantly associated with the CAPD 
outcome. Single (unmarried) patients were more likely to be successful on PD, in comparison 
to married patients (OR=3.02; 95% CI=1.17-7.75; p=0.021). Lastly, patients who were non-
adherent were less likely to be a PD success in comparison to patients who were adherent 
(OR=0.40; 95% CI=0.19-0.83; p=0.007). 
 
Table 3.6 demonstrates  the different rates of the PD outcomes,  with a low transplant rate 
of 6.6%; survival rate of 51% being highest; followed by 25% mortality rate, cardiovascular 
disease rate  18%,  transfer to HD 13% , transfer to private facility 10%. There was also a 
peritonitis rate of 1 episode per 27 patient months.  
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 Table 3.6 Peritoneal Outcome Rates  
Outcomes Rates 
Cardiovascular disease 18% 
Peritonitis rate  1 episode of peritonitis per 27 patients 
months 
Transfer to HD  13% 
Transfer to other  centres  10% 
Mortality rate 25% 
Survival rate 51% 
Transplant rate 6.6% 
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CHAPTER FOUR  
4 Discussion and Limitations 
 
4.1 Discussion 
 
The main objectives of this study were to investigate the impact of demographic and 
socioeconomic factors on the outcomes of CAPD, as well as the role of co-morbid diseases  in 
the outcomes of CAPD. 
 
The distribution of PD outcomes (Figure 3.2) showed relatively higher PD failure compared to 
PD success, of 53.3% and 46.7% respectively. This result is relatively similar to the  4 year 
study  in Natal by Parsoo et al which showed 45.4% PD success and 54.5% PD failure (28).  
There was a single centre study in Ljubljana, Slovenia of 286 patients on PD between 2004 to 
2010, where 26.8% of patient were transplanted, 36.2% were still on PD, 35.6% died and 1.4% 
were lost to follow up; overall PD success was 63% and PD failure 37% (17). 
 
The distribution of co-morbidity in this study showed that most of the patients were 
hypertensive, followed by HIV infection and diabetes mellitus; 18.63% of the patients had 
cardiovascular complication. The 2016 SA Renal Registry report showed that 33.7% of patients 
had hypertensive nephropathy and 14.4% diabetic nephropathy; 9.3% were HIV positive (7). 
According to the Latin American Registry of Dialysis and Transplantation, diabetes remained 
the major cause of CKD in RRT, with the highest incidence recorded in Puerto Rico at 66.8%, 
Mexico 61.8%, Colombia 42.5% and the lowest incidence in Cuba and Uruguay at 26.2% and 
23.2% respectively (52). 
 
Literature review revealed conflicting findings, with some studies (25,28) showing that 
demographic and socioeconomic status did not influence the outcomes of CAPD while others 
(23,24) reported that these factors had an impact on the outcomes of CAPD. In addition, other 
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studies have failed to show a difference in outcome of CAPD between developed and 
developing countries (23,24). Poor outcomes of CAPD have been associated with the 
following factors: inadequate social amenities, no electricity, lack of proper housing or 
informal housing, high occupancy to bedroom ratio, no running water, number of years of 
education; these factors are prevalent in SA (25, 28). 
 
The majority of patients in this study were black, unemployed and dependent on disability 
grants for income, and residing in economically disadvantaged areas with limited  education. 
These demographic factors apply to patients on dialysis in most government institutions, as 
most patients who are treated in the public or government hospitals cannot afford medical 
aid or private health care. The patients were aged from 15 to 62 years, with mean age of 38.7 
(± 10.6) years, with the majority of patients male and single (as shown in Table 3.1). The 
majority of the patients 56% were on disability grant (Figure 3.1) 
   
The distribution is consistent with 2017 report of the SA Renal Registry which showed that 
the majority of patients on RRT were black (53.2%); 59.3% were male. The mean age in public 
sector is 43 (± 13.5) years, lower than that of private patients where the mean age is 54.7  (± 
14.3) years;  the overall mean age was 51.3 ± 15.0 years  (7). The mean age in other developing 
countries is similar and ranged from 41 ± 22 years in Sudan (53). The mean age in the 
developed countries tends to be higher, for example mean age in the United States was 79 ±  
4 years (54). 
 
Though the Fisher exact test showed statistically significant distribution of CAPD outcomes 
with age, showing significant proportions of CAPD success and failure among different age 
categories (Figure 3.3), the univariate and multivariate logistic regression where age was 
fitted as a continous variable showed no significant association with CAPD outcome (Table 
3.4 and Table 3.5). The literature  has shown different outcomes with age. There are studies 
that reported that age was associated with CAPD outcomes; some studies showed that 
mortality was higher in elderly patients, (55,56). Another study identified age, systolic blood 
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pressure and the absolute quantity of small solutes removed at baseline as independent 
predictors of mortality (57). Clinical outcomes of elderly patients on peritoneal dialysis 
showed decrease in survival time with increasing age and presence of co-morbidity (56). PD 
has also proven to be more beneficial in patients (<60 years) with no co-morbidity, compared 
to HD which was more beneficial in older patients (58).   
 
However, Nessim et al did not find any relationship between peritonitis complications that 
can result in peritoneal failure and older age in the subgroup of patient initiated on dialysis in 
Canada in 2001-2005 (59).  A study that looked into higher rates of infection related 
complications with advancing age in two eras concluded that ‘the higher peritonitis rate 
represented an era effect as age was not associated with peritonitis in the patients initiated 
on PD in 2001-2005’ (60).  
 
However, a study showed that older patients have unique needs as they encounter different 
barriers to peritoneal dialysis which included deterioration of vision, decline in cognitive 
function, frailty and sometimes poorer family support (61). These can be challenging as they 
may result in complications like infection, inadequate dialysis as well as non-compliance. 
However there are measures that can be employed to overcome  these challenges, such  as 
involving the social worker and to get the family involved, as previous  studies have shown 
that assisted PD could overcome these barriers. Automated PD has also been found to 
improve the outcomes of PD in older patients (62). However, there are budgetary  constraints 
that limit the use of assisted PD or automated peritoneal dialysis in resource-poor settings. 
 
Studies by Chen et al (Taiwan) and Martin et al (Brazil) showed that age greater than 65 years 
and low levels of education were independently associated with increased risk of peritonitis 
(37, 63). Chen et al, in a retrospective cohort study of a Taiwanese PD population with 12 
years of follow up, concluded that ‘’lower education is a major risk factor for  PD related 
peritonitis independent of age, sex, hypoalbuminemia and co morbidity’’ (63). They also 
attributed low levels of education as a risk factor for peritonitis, especially in the first six 
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months of starting PD (63). The study in Brazil, however, concluded that educational level, 
geographical factors, race and centre size were risk factors for developing the first episode of 
peritonitis, independent of socioeconomic factors, PD modality and co morbidities (37). 
   
The current study (Figure 3.5), did not show any association of the level of education with the 
outcomes of PD. There was a study which showed that although a lower level of education 
was the risk factor for peritonitis and technique failure, there was no significant difference in 
all cause mortality between patients with lower educational levels compared with higher 
educational levels. Comprehensive training by a multidisciplinary team may overcome the 
lower levels of education in PD patients (64). Most centres have therefore put in place 
extensive educational programmes and protocols where patients are admitted for a week or 
more, when they are started on peritoneal dialysis; CMJAH also has a similar educational 
program where patients are admitted for educational and training purposes when started on 
peritoneal dialysis. This is where they are taught in their own language for several hours daily,  
ensuring that they understand everything they need to know about PD. There is room to try 
and do more research to determine if the above educational programme is adequate or if 
there are other strategies to be explored in order to improve PD success despite the 
educational level of the patient.   
 
Employment also did not have a significant impact on the outcomes of peritoneal dialysis 
(Figure 3.6).  Most of the patients in this study were not working and were awarded disability 
grants. As part of the dialysis education, they were made aware of their eligibility for a 
disability grant if they did not have financial support. This is one of the initiatives that are 
undertaken, in order to limits patients’ non-compliance due to financial constraints. Where 
patients are working, their employers are informed about their treatment and the need to 
come for regular treatment and follow up, if necessary. Most studies show that patients' 
employment rate is low, compared to the general population, and patients who were on 
automated dialysis were the ones who were more likely to be employed (65). This might 
explain how patients who are on medical aid and in private care (where automated PD is 
offered) are able to maintain their employment. Though unemployment may impact 
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adversely on the patient’s  lifestyle, the measures taken seem to be adequate for employment 
not to play a significant role in the outcomes of PD.  
 
 Imanishi Y et al in Japan showed  that employment and education status  were inversely 
association with the clinical outcome and mortality. The study further demostrated 
employment not educational was inversely associated with hospital (66). A study from China 
showed that lack of income was associated with increased risk of all causes of cardiovascular 
death and initial peritonitis (31). A study from Korea demonstrated, in a multivariate analysis, 
a significant association of frailty with unemployment, lower level of e ducation and age, 
among other factors associated with higher mortality and hospitalization (67).  
  
There is no clear consensus of the role of marriage or family in the outcome of peritoneal 
dialysis in the literature. In a study from Brazil, there was a significant difference between the 
HD and PD groups, with 82.1% of the PD group being married which might reflect 
fundamental factors of lack of support for those living alone and the importance of a spouse 
for assisting with PD (68). A study by Chow et al showed that marital status and social isolation 
among other factors did not affect the risk of hospitalization for PD patients in Hong Kong ( 
69). 
 
In this study, marital status was not shown to  influence  CAPD success and failure on the 
Fisher exact test. However, the multivariate analysis (Table 3.5) showed that single patients 
were three times more likely to succeed (odd ratio 3.02). Marital stutus was significantly 
associated with CAPD  outcome (p=0.021).  These finding  could be due to chance as the study 
sample size was small and further research is needed.  Shen et al, in a study in the US, showed 
that   single status was not associated with technique failure; however, patients who were 
divorced/separated or widowed were more likely to fail  PD (70).  There is limited data in the 
literature, especially with regards to the patient on PD; therefore more studies need to be 
done to establish whether marital status plays a role in overall PD outcome. 
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There is evidence that good family support helps in the overall commitment and favourable 
outcomes of patients on dialysis (71). There were also studies from China that showed that 
married couples had earlier referral to nephrologists than single patients, with later referral 
associated with a higher cardiovascular mortality (72, 29).  However, there is still more 
research to be done to validate whether being married increases attention to detail and 
influences management and outcomes. 
 
There is not much data in the literature exploring family views on peritoneal dialysis. One of 
the disadvantages of peritoneal dialysis is that it can be stressful for the family members who 
are assisting with the dialysis and it may require a life style change for the family as well. The 
experience of living with patient with chronic disease changes the families’ attitude  and 
practices creating the new meanings causing the family to change their habits and expections 
because of the new reality (73). There is also the need for storage space which may prove to 
be  challenging especially in settings where many patients live in impoverished and small 
homes without adequate storage space. 
 
Gender did not have a significant influence on PD outcomes (Figure 3.3), consistent with 
several studies that showed no difference in PD outcomes in either sex (37 and 74). There is 
controversy regarding  the effects of gender on the outcomes of PD  (75). Other studies 
showed that gender, especially when other risk factors were adjusted, did not have any 
impact on peritoneal dialysis outcomes nor was it associated with increased risk of peritonitis 
(76, 16, 77) . However, some studies showed adverse outcomes in females, with diabetes 
mellitus with females having higher mortality, catheter loss and a greater risk of peritonitis 
than males (78, 79).   
 
Race is another factor which had no impact on the outcomes of PD in this study (Figure 3.7).  
Studies have yielded variable results when it comes to the role of race, if any, on the outcome 
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of PD.  Black race has been associated with increased incidence of modality failure (80, 81). 
There is also an increased rate of peritonitis in Black patients as compared to other races (82). 
However, some studies showed that Caucasians had more adverse effects and more failure 
of PD than Black patients (83, 84). Singh N et al  showed that race did not affect catheter 
survival, which can determine PD outcome (85). However, due to the complexities in the 
distribution of race across the world, comparing results may not be equivalent because each 
study is adjusted for different factors (83) and in some cases, sample size may contribute to 
the interpretation of race on PD outcome. There is also the question whether survival of 
dialysis in different races may be more on a biological basis and may require  genetic analysis 
(83). 
 
 There are studies that demonstrated that patient location affected their outcomes. Okpechi 
et al, in a study from Cape Town, showed that some patients lived in homes with poor 
sanitation and were very overcrowded, where they  presented with peritonitis, resulting in 
PD failure (1). However in this study, the location of patients did not show any significant 
impact on the outcomes of PD (Figure 3.8). In a study done in the United States, there was no 
difference in outcomes between patients from the rural and urban dialysis areas (86). Tonelli 
et al, in a study from Canada, showed that patients residing in remote areas had lower risk of 
transfer to HD, but had a higher risk for death (87). Due to financial constraints, the PD Unit 
at CMJAH is no longer able to undertake home visits. It would be interesting to ascertain if 
the home visit would further improve outcomes and decrease the incidence of peritonitis. 
 
There are several studies that demonstrated that diabetes mellitus contributed negatively to 
technique survival and the overall prognosis of the patient on CAPD (29, 88). The study in 
Limpopo province showed that the mortality risk was five times higher among diabetic 
patients on CAPD, relative to non-diabetic patients on HD (89). Nessim et al showed an 
association between diabetes and gender, with increased risk of peritonitis in female patients 
with diabetes mellitus (90). In contrast, this study did not demonstrate any contribution of 
diabetes mellitus to the outcome of PD (Table 3.3). However, the small number of diabetic 
patients on PD in this study may account for this finding. While there is substantial evidence 
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in the literature that shows that diabetes contributed to PD failure (91, 92),  there are a few 
studies  have shown improved technique  survival and better long term patient survival of  
diabetic  PD patients (93,  94).  
 
There was no association of PD outcome with HIV infection in this study (Table 3.3). Previous 
studies have shown that with the introduction of antiretroviral therapy, survival of HIV-
infected patients on dialysis has increased and PD is a suitable modality of RRT, with no 
significant effects on morbidity and mortality (95, 96). However, HIV infection was associated 
with increased risk of peritonitis (97). Another study showed that asymptomatic HIV patients  
had low mortality and catheter loss compared to patients with advanced HIV with CD4 less 
than 200  (98). In keeping with national guidelines, HIV positive patients who were enrolled 
in the PD programme were managed together with the Infectious Disease department.  The 
patients were  optimised on antiretroviral treatment for at least six months and their viral 
load monitored to make sure they were suppressed. The six month time period is also useful 
as it gives patients time to adapt and adjust to the nature of their illness and proves their 
compliance; this could be a reason for their success on PD. 
 
Hypertension is a major risk factor for cardiovascular disease and about 86% of patients with 
ESKD are diagnosed with hypertension and more than 50% of patients on PD have 
hypertension (99). In this study, though the frequency of hypertension was 91.2%, it did not 
impact on the outcome of PD Table 3.3. The reason for the lack of effect of hypertension on 
the outcome of PD, especially cardiovascular, may presumably be due to bias, since the 
majority of the patients were hypertensive. The study from Australia reported that blood 
pressure was associated with increased risk of Tenchkoff catheter loss and increased risk of 
peritonitis (100); systolic blood pressure, in addition to age and small solute clearance, were 
all significant predictors of death in a study from the Netherlands (56).  
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Cardiovascular diseases are collectively the most common cause of death in patients on 
dialysis (101, 102). There is evidence that patient with ESKD are at the highest risk of 
cardiovascular-related mortality due to traditional and non traditional risk factors (91). There 
is also increased risk of peritonitis in patients with coronary artery disease and congestive 
heart failure (79). There was no impact of cardiovascular disease on the outcome of PD in this 
study (Table 3.3).  However, the dialysis population at CMJAH, as with other public sector 
institutions in South Africa, is a highly selected group of patients with minimal co-morbidity 
at initiation of dialysis. There are a few studies that showed that cardiovascular disease did 
not have any impact on the risk of peritonitis (103, 104). A systematic review of 21 studies 
from 13 countries (England and Asia among them) reported that PD is a safe and efficient 
alternative in patients with congestive heart failure (105). 
 
There is limited data on PD adherence and outcomes, suggesting that the problem is not 
adequately addressed (106). The adherence issue is very important as non-adherence can 
result in increased risk of mortality and hospitalization (106). Non-adherence in PD patients 
has been associated with high incidence of infectious complications, especially peritonitis and 
increased incidence of death (107, 108). This study showed a significant association of 
adherence with PD outcomes (Figure 3.9). The only measure for assessing adherence in this  
study was  based on the failure to attend follow up on the clinic dates, as it was a retrospective 
study. Problems such as fluid overload and poor clearance of creatinine may be other criteria 
and may also differentiate those who are not dialysing adequately due to technical problems 
with their Tenchkoff catheters or membrane problems, from the ones that are not dialysing 
at all. Univariate and multivariate analyses further confirmed the importance of patient 
adherence in this study (Table 3.4 and Table 3.5 respectively), as patient who were non 
compliant were less likely to be a PD success as compared with the compliant patient. This 
further confirms the importance that non-adherence plays in the overall outcomes of the PD. 
 
It is important to note that even though many studies have shown that non-adherence is 
associated with adverse outcomes, it has proven to be a challenge to describe the  
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parameters used to measure non-adherence in patients who are on dialysis.  In most studies, 
each study had different measures that were used to define non-compliance: whether being 
creatinine clearance, fluid overload, failure to attend follow up or collect medication and in 
some cases, not knowing their medication or not being able to describe how they dialysed. In 
one study from the USA, non adherence was defined as performance of less than 90% of 
prescribed exchanges (109).   
 
There are studies that tried to assess factors that influence adherence in patients on PD. Griva 
et al showed that non-adherence was associated with socio-economic and demographic 
factors and duration of PD treatment (106). There is a need for high quality research to look 
into these factors in more detail, in order to recommend appropriate interventions. Being a 
retrospective study, data was limited with regards to fully exploring the reasons for non-
adherence and the impact of socioeconomic and demographic factors on non-adherence.  
  
This study showed a peritonitis rate of 1 episode of peritonitis per 27 patient  months (Table 
3.6). The peritonitis rate is within the acceptable ISPD recommendation (1 episode of 
peritonitis per 18 patient months). The result was much better than the Sudanese rate which 
was 1 episode of peritonitis per 14 patients months, which subsequently improved, by 
implementing ISPD guidelines, to one episode per 50.6 patients month (110). Their current 
rate is now comparable to developed countries like Canada, whose peritonitis rate is 1 
episode per 30  patient months (111). 
 
Cardiovascular morbidity and mortality is increased in PD patients due to accelerated 
artherosclerosis and calcification (112).  There is a high prevalence rate of left ventricular 
hypertrophy, which is estimated to range from 44% to over 90%, and predisposes PD patients 
to heart failure/ circulatory congestion. Diastolic dysfunction plays an important role as most 
PD patients who develop heart failure have normal ejection function (113). 
 
46 
 
 
The patient  survival rate at the end of five years was 51% (Table 3.6).These results are 
comparable to results in other centres, where survival at 5 years was 43% (114). The  
Australian and New Zealand Dialysis and Transplant Registry showed that the five year 
survival of PD patients was 44%(115).  In a study in Cape Town, the technique survival at 5 
years 39% , while the patient survival was 63% (116).   The mortality rate was 25% over five 
years see (Table 3.6); the mortality is high, compared to the study done in Cape Town, where 
the mortality  rate was  11.6% (116). The mortality rate was however comparable to the 
mrrtality rate of 24.4% in study done in Turkey (114). The mortality was lower than the 
mortality rate of the study done in Natal of 31% (118). 
 
The transfer of patients from PD to HD occurred in 13% (Table 3.6). The switch from PD to HD 
of more than 35 % had been reported (117). Unsal et al in a retrospective study in Turkey 
showed a transfer rate of 24.8% (114). The most common cause for switching was peritonitis 
and catheter related complications (117).The transplant rate of 6.6% was low in this study 
(Table 3.6), and is lower than the transplant rate of 12.7% of PD patients in Turkey in a 10 
year retrospective study (114) and lower than the transplant rate  of 26% in the study done 
in the UK over 7 years (17). The low transplant rate in the study was consisted with low 
transplant rate overall in South Africa (7). 
 
4.2 Limitations 
  
Home visits were no longer done due to financial constraints, so most of the patients were 
started on CAPD based on the information they provided to the staff, with proof of residence. 
There was therefore no way of verifying that space, sanitation and access to water were 
present. In this study, it was therefore not possible to assess to what extent this influenced 
the outcome of PD.  The study did not however explore whether lack of home visits played 
any role in rate of peritonitis .     
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Being a retrospective study, some of the information was not available that could have 
brought more clarity to what extent demographic and socioeconomic status impacted on  
CAPD outcomes. For example, the reasons for non-adherence and establishing whether 
demographic and socioeconomic factors played a role in non-adherence were not 
established. 
 
There was insufficient data to accurately establish the cause of death, as many patients died 
at home. In addition, most of the data was limited to what was documented in the clinical 
notes, with some missing information. 
 
The sample of collected data was too small in some categories. The stastically significant 
finding of the very low sample base  (sample size of less than n=10) may be due to chance and 
therefore  the association of marital status and CAPD success must be taken with caution. 
 
Lastly there is the strong possibility of confounding factors that limit the accuracy of the study 
resul 
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CHAPTER FIVE 
5 Reccomendations and Conclusions 
5.1 Recommendations 
 
 Since non adherence seems to play a major role in the adverse outcomes of PD, future 
prospective studies are needed to understand the difficulties patients encounter and the 
reasons for their nonadherence. It might be helpful to invest in home visits again and utilise 
the assistance of social workers, dieticians and psychologists who are specifically trained in 
nephrology, to fully understand the dynamics involved with patient adherence to the PD 
programme.  
 
There is therefore further research needed to fully understand the impact of demographic 
and socioeconomic factors on the outcomes of PD. More prospective studies are required 
that deal in details with the dynamics that are involved in PD. The study should include other 
disciplines (psychology, social worker, dietician etc.) as well as family members, to fully 
understand the impact on the outcome of PD. In this way, the treatment of PD will be holistic 
and thereby improve the outcomes and decrease the costs involved in managing the 
complications of PD.  
 
5.2 Conclusions 
 
This study showed that non-adherence impacted significantly on CAPD outcomes as shown 
by the  univariate and  multivariate analyses . It also shows that even though there is 
significant distribution of CAPD outcomes with age, further analysis showed that age does not 
impact the outcome of CAPD.   Lastly, though the distribution of CAPD outcomes with marital 
status was not significant, further analysis showed that  single status of patients were more 
likely to have PD success which could be due to chance due to the small sample size.  
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